Ilet Bionic Pancreas

Search documents
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
GlobeNewswire· 2025-07-02 11:30
IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company’s website in the “ ...
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
Globenewswire· 2025-05-06 20:02
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. First Quarter 2025 Financial Results & Key Metrics Non-GAAP Financial Measures Beta Bionics, Inc. (the "Company") prepares and presents the Company's financial statements in accordance with U.S. General ...
Beta Bionics Inc(BBNX) - 2024 Q4 - Earnings Call Transcript
2025-03-25 21:30
Beta Bionics (BBNX) Q4 2024 Earnings Call March 25, 2025 04:30 PM ET Company Participants Blake Beber - Head - Investor RelationsSean Saint - Board Member, President & CEOStephen Feider - CFOTravis Steed - Managing Director - Equity ResearchMike Kratky - Senior Managing Director - Medical Devices & TechnologyMathew Blackman - Managing DirectorJeffrey Cohen - MD - Equity Research Conference Call Participants Matt O'Brien - AnalystBrooks O'Neil - Senior Research Analyst Operator Good afternoon, and welcome to ...
冲刺IPO!医械独角兽融资超14亿
思宇MedTech· 2025-02-17 04:20
2024年2月14日,Kestra Medical 提交了一份S-1表格,确认其计划通过首次公开募股(IPO)上市,并且设定了筹集约1亿美元的目标。 Kestra Medical 是一家专注于开发创新医疗设备的公司,致力于通过先进的技术改善心脏健康管理,其核心产品是可穿戴式心脏复律除颤器(Wearable Cardioverter Defibrillator, WCD),旨在为高风险患者提供持续的心脏监测和保护。 自动检测与治疗: 当检测到危及生命的心律失常(如心室颤动或心动过速)时, 设备能够自动提供电击治疗,以恢复正常心律。 这种自动化的功能是其核 心优势之一,能够在患者无意识或无法自救的情况下,迅速采取行动。 记录其他心律失常: 除了能够处理危及生命的心律失常外,ASSURE WCD还能 检测和记录其他可能需要临床干预的心律失常 。这为医生提供了更全面的 患者心脏活动数据,有助于后续的诊断和治疗。 此外,该系统还 兼容 Kestra Medical 的数字健康平台,方便患者和医生及时进行通信。 平台通过大量的个人数据整理,通过终端呈现给患者,促进患者参 与自己的康复过程。 # A S S U R E W ...